Emergent BioSolutions Subsidiary Announces Contract Modification

On January 10, 2012, Emergent Product Development Gaithersburg Inc., a wholly-owned subsidiary of Emergent BioSolutions Inc., (NYSE: EBS) entered into a no-cost modification of its contract dated September 17, 2010, with the Biomedical Advanced Research and Development Authority of the U.S. Department of Health and Human Services for the development of a recombinant protective antigen (rPA) anthrax vaccine..

The modification extends the base period of performance of the contract at no additional cost from September 19, 2010 through September 18, 2012, to September 19, 2010 through January 20, 2013, and modifies the Milestone Table and Deliverables to incorporate the new base period of performance.